Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: a tertiary academic center experience
Objectives Castration-resistant prostate cancer (CRPC) has retained a guarded prognosis,
with historical survival estimates of 18 to 24 months. However, the landscape of available
therapy has changed, and the emphasis has altered from supportive to active treatment. Few
large series from real-world populations exist in the contemporary era with fully mature
survival data to confirm the indication based on clinical trials that patients with CRPC are
surviving far longer than the historical estimates. We aim to review a large patient cohort with …
with historical survival estimates of 18 to 24 months. However, the landscape of available
therapy has changed, and the emphasis has altered from supportive to active treatment. Few
large series from real-world populations exist in the contemporary era with fully mature
survival data to confirm the indication based on clinical trials that patients with CRPC are
surviving far longer than the historical estimates. We aim to review a large patient cohort with …